MTOR and renal cell carcinoma: At present, therapeutic drugs targeting HIF, VEGF, and phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) are important first-line treatment options for advanced RCC patients, but only a small proportion of patients benefit from them [16].